CPDC's Radiopharmaceutical Manufacturing Facility Receives Clearance from FDA

Thursday, January 9, 2020 General News
Email Print This Page Comment bookmark
Font : A-A+

HAMILTON, ON, Jan. 9, 2020 /PRNewswire/ - The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that, following a successful U.S. Food and Drug Administration (FDA) inspection in July, CPDC's site in Hamilton, Ontario, is cleared to ship products to the U.S. 

Justyna Kelly, interim CEO of CPDC, stated, "We are delighted with the outcome of the FDA inspection. We look forward to continuing to support the clinical development efforts of our many global partners and we're thankful for the excellent support from all of our staff."

FDA's inspection of CPDC closed with no 483 observations and was classified as NAI (No Action Indicated).

About CPDCThe Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.

Cision View original content:http://www.prnewswire.com/news-releases/cpdcs-radiopharmaceutical-manufacturing-facility-receives-clearance-from-fda-300983946.html

SOURCE Centre for Probe Development and Commercialization



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store